Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
— Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical models — Clinical data supports co-administration of an MC4R agonistwith tirzepatide as a safe, potentially synergistic approach to weight management — PL7737 IND-enabling toxicology underway, with an IND submission and clinical trial initiation planned for the first half of […]